Skip to main content
SpringerLink
Log in

Olanzapine, a novel atypical antipsychotic, reversesd-amphetamine-induced inhibition of midbrain dopamine cells

  • Original Investigation
  • Published:
Psychopharmacology Aims and scope Submit manuscript

Abstract

This study compared the ability of the novel atypical antipsychotic olanzapine with that of clozapine to reverse thed-amphetamine-induced inhibition of substantia nigra (A9) and ventral tegmental area (A10) dopamine (DA) cells. Extracellular single-unit recordings were made from A9 and A10 DA cells in anesthetized rats. When administered alone, neither olanzapine nor clozapine altered the firing rate of A9 or A10 DA cells. Administration ofd-amphetamine (0.5, 1.0 and 2.0 mg/kg, IV, decreased the firing rate of A9 and A10 DA cells. Olanzapine completely reversed the inhibitory effects ofd-amphetamine on A10 DA cells (ED100=0.18 mg/kg, IV) and on A9 DA cells (ED100=1.0 mg/mg, IV). Clozapine completely reversed the inhibitory effects ofd-amphetamine on A10 DA cells (ED100=3.8 mg/kg, IV), but only partially reversed the effects ofd-amphetamine on A9 DA cells at the highest dose tested (8.0 mg/kg, IV). Thus, olanzapine, like clozapine, was more potent in reversing the effects ofd-amphetamine on A10 than A9 DA cells. In addition, olanzapine was more potent than clozapine in the reversal ofd-amphetamine effects on A9 and A10 DA cells. These results indicate that olanzapine and clozapine have similar effects on DA unit activity and predict that olanzapine should have an atypical antipsychotic profile in man.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  • Beasley CM, Tollefson GD, Sanger T, Tran P, Holman S, and the North American Olanzapine Study Group (1996) Olanzapine versus placebo and haloperidol: acute phase results of the North American double-blind olanzapine trial. Neuropsychopharmacology 14:105–118

    Google Scholar 

  • Benvenga MJ, Leander JD (1995) Olanzapine, and atypical antipsychotic, increases rates of punished responding in pigeons. Psychopharmacology 119:133–138

    Google Scholar 

  • Bernardini GL, Gu X, Viscardi E, German DC (1991) Amphetamine-induced and spontaneous release of dopamine from A9 and A10 cell dendrites: an in vitro electrophysiological study in the mouse. J Neural Transm 84:183–193

    Google Scholar 

  • Borison RL (1995) Clinical efficacy of serotonin-dopamine antagonists relative to classic neuroleptics. J Clin Psychopharmacol 15:24S-29S

    Google Scholar 

  • Bowery B, Rothwell LA, Seabrook GR (1994) Comparison between the pharmacology of dopamine receptors mediating the inhibition of cell firing in rat brain slices through the substantia nigra pars compacta and ventral tegmental atea. Br J Pharmacol 112:873–880

    Google Scholar 

  • Bunney BS (1977) Central dopaminergic systems: two in vivo electrophysiological models for predicting therapeutic efficacy and neurological side effects of putative antipsychotic drugs. In: Hanin I, Usdin E (eds) Animal models in psychiatry and neurology. Pergamon Press, New York, pp 91–104

    Google Scholar 

  • Bunney BS, Aghajanian GK (1973) Electrophysiological effects of amphetamine on dopaminergic neurons. In: Snyder S, Usdin E (eds) Frontiers in catecholamine research. Pergamon Press, New York, pp 957–962

    Google Scholar 

  • Bunney BS, Aghajanian GK (1974) A comparison of the effects of chlorpromazine, 7-hydroxychlorpromazine and chlorpromazine sulfoxide on the activity of central dopaminergic neurons. Life Sci 15:309–318

    Google Scholar 

  • Bunney BS, Aghajanian GK (1975) Antipsychotic drugs and central dopaminergic neurons. a model for predicting therapeutic efficacy and incidence of extrapyramidal side effects. In: Sudilovsky A, Gershon S, Beer B (eds) Predictability in psychopharmacology: preclinical and clinical correlations. Raven Press, New York, pp 225–245

    Google Scholar 

  • Bunney BS, Aghajanian GK (1976) The effect of antipsychotic drugs on the firing of dopaminergic neurons: a reappraisal. In: Sedvall G, Uvnas B, Zotterman Y (eds) Antipsychotic drugs: pharmacodynamics and pharmakokinetics. Pergamon Press, New York, pp 305–318

    Google Scholar 

  • Bunney BS, Walters JR, Roth RH, Aghajanian GK (1973) Dopaminergic neurons: effects of antipsychotic drugs and amphetamine on single cell activity. J Pharmacol Exp Ther 185:560–571

    Google Scholar 

  • Bymaster FP, Colligaro DO, Falcone JF, Marsh RD, Moore ND, Tye NC, Seeman P, Wong DT (1996a) Radioreceptor binding profile of the atypical antipsychotic olanzapine. Neuropsychopharmacology 14:87–96

    Google Scholar 

  • Bymaster FP, Perry KW, Hemrick-Luecke SK, Fuller RW (1996b) Neurochemical evidence for antagonism by olanzapine of dopamine, serotonin alphal-adrenergic and muscarinic receptors in vivo in rats. Psychopharmacology 124:87–94

    Google Scholar 

  • Carlsson A, Lindqvest M (1963) Effect of chlorpromazine or haloperidol on formation of 3-methoxytyramine and normetanephrine in mouse brain. Acta Pharmacol Toxicol 20:140–144

    Google Scholar 

  • Chiodo LA, Bunney BS (1983) Typical and atypical neuroleptics: differential effects of chronic administration on the activity of A9 and A10 midbrain dopaminergic neurons. Neuroscience 3:1607–1619

    Google Scholar 

  • Chiodo LA, Bannon MJ, Grace AA, Roth RH, Bunney BS (1984) Evidence for the absence of impulse-regulating somatodendritic and synthesis-modulating nerve terminal autoreceptors on subpopulations of midbrain dopamine neurons. Neuroscience 12:1–16

    Google Scholar 

  • Claghorn J, Honigfeld G, Abuzzahab FS Sr, Wang R, Steinbock R, Tuason V, Klerman G (1987) The risks and benefits of clozapine versus clorpromazine. J Psychopharmacol 7:377–384

    Google Scholar 

  • Connell PA (1958) Amphetamine psychosis. Maudsley Monograph no 5. Oxford University Press, London

    Google Scholar 

  • Corrodi H, Fuxe K, Hokfelt T (1967) The effect of some psychoactive drugs on central monoamine neurons. Eur J Pharmacol 1:363–368

    Google Scholar 

  • Davis KL, Kahn RS, Ko G, Davidson M (1991) Dopamine in schizophrenia. a review and reconceptualization. Am J Psychiatry 148:1474–1486

    Google Scholar 

  • De la Chapelle A, Kari C, Nurminen M, Hernberg S (1977) Clozapine-induced agranulocytosis. Hum Genet 37:183–194

    Google Scholar 

  • Deutch AY (1993) Prefrontal cortical dopamine systems and the elaboration of functional corticostriatal circuits: implications for schizophrenia and Parkinson's disease. J Neural Transm [GenSect]91:197–221

    Google Scholar 

  • Fuller RW, Snoddy HD (1992) Neuroendocrine evidence for antagonism of serotonin and dopamine receptors by olanzapine (LY 170053), an antipsychotic drug candidate. Res Commun Chem Pathol Pharmacol 77:87–93

    Google Scholar 

  • Goldstein JM, Litwin LC, Sutton EB, Malick JB (1986) The role of 5-HT2 receptor blockade on amphetamine (AMP) inhibition of dopamine (DA) cell firing. Fed Proc 45:436

    Google Scholar 

  • Goldstein JM, Litwin LC, Sutton EB, Malick JB (1989) Effects of ICI 169,369, a selective serotonin2 antagonist, in electrophysiological tests predictive of antipsychotic activity. J Pharmacol Exp Ther 249 [no 3]:673–679

    Google Scholar 

  • Goldstein JM, Litwin LC, Sutton EB, Malick JB (1993) Seroquel: electrophysiological profile of a potential atypical antipsychotic. Psychopharmacology 112:293–298

    Google Scholar 

  • Grace AA (1991) Phasic versus tonic release and the modulation of dopamine system responsivity. a hypothesis for the etiology of schizophrenia. Neuroscience 41:1–24

    Google Scholar 

  • Grace AA, Bunney BS (1979) Paradoxical GABA excitation of nigral dopaminergic cells: indirect mediation through reticular inhibitory neurons. Eur J Pharmacol 59:211–218

    Google Scholar 

  • Griffith JJ, Oates J, Cavanaugh J (1968) Paranoid episodes induced by drugs. JAMA 205:39

    Google Scholar 

  • Griffith RW, Saameli K (1975) Clozapine and agranulocytosis. Lancet 2:657

    Google Scholar 

  • Hagger C, Buckley P, Kenny JT, Friedman L, Ubogy D, Meltzer HY (1993) Improvement in cognitive functions and psychiatric symptoms in treatment-refractory schizophrenic patients receiving clozapine. Biol Psychiatry 34:702–712

    Google Scholar 

  • Juul Povlsen U, Noring U, Fog R, Gerlach J (1985) Tolerability and therapeutic effect of clozapine: a retrospective investigation of 216 patients treated with clozapine for up to 12 years. Acta Psychiatr Scand 71:176–185

    Google Scholar 

  • Kane J, Honigfeld G, Singer J, Meltzer HY, the Clozaril Collaborative Study Group (1988) Clozapine for the treatment-resistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 45:789–796

    Google Scholar 

  • Lieberman JA, Johns CA, Kane JM, Rai K, Pisciotta AV, Saltz DL, Howard A (1988) Clozapine induced agranulocytosis: noncross reactivity with psychotropic drugs. J Clin Psychiatry 49:271–277

    Google Scholar 

  • Losonczy MF, Davidson M, Davis KL (1987) The dopamine hypothesis of schizophrenia. In: Meltzer HY (ed) Psychopharmacology: the third generation of progress. Raven Press, New York, pp 715–726

    Google Scholar 

  • Meador-Woodruff JH, Damask SP, Watson SJ (1994) Differential expression of autoreceptors in the ascending dopamine systems of the human brain. Proc Natl Acad Sci USA 91:8287–8301

    Google Scholar 

  • Meltzer HY, Bastani B, Kwon B, Ramirez L, Burnett S, Shapre J (1989) A prospective study of clozapine in treatment-resistant schizophrenic patients. I. Preliminary report. Psychopharmacology 99 [Suppl]:S68-S72

    Google Scholar 

  • Miller DD, Perry PJ, Cadoret RJ, Andreasen NC (1994) Clozapine's effect on negative symptoms in treatment-refractory schizophrenics. Comp Psychiatry 35:8–15

    Google Scholar 

  • Moore NA, Tye NC, Axton MS, Risius F (1992) The behavioral pharmacology of olanzapine, a novel “atypical” antipsychotic agent. J Pharmacol Exp Ther 262:545–551

    Google Scholar 

  • Nyberg S, Farde L, Halldin C (1996) A PET study of 5-HT2 and D2 dopamine receptor occupancy induced by olanzapine in healthy subjects. Neuropsychopharmacology (in press)

  • O'Brien DP, White FJ (1987) Inhibition of non-dopamine cells in the ventral tegmental area by benzodiazepines: relationship to A10 dopamine cell activity. Eur J Pharmacol 142:343–354

    Google Scholar 

  • Pucak ML, Grace AA (1994) Evidence that systemically administered dopamine antagonists activate dopamine neuron firing primarily by blockade of somatodendritic autoreceptors. J Pharmacol Exp Ther 271:1181–1192

    Google Scholar 

  • Rasmussen K, Stockton ME, Czachura JF (1991) The 5-HT3 receptor antagonist zatosetron decreases the number of spontaneously active A10 dopamine neurons. Eur J Pharmacol 205:113–116

    Google Scholar 

  • Sanchez C, Arnt J, Dragsted N, Hyttel J, Lembol HL, Meier E, Perregaard J, Skarsfeldt T (1991) Neurochemical and in vivo pharmacological profile of sertindole, a limbic-selective neuroleptic compound. Drug Dev Res 22:239–250

    Google Scholar 

  • Serby M, Angrist B, Leiberman A (1978) Mental disturbance during bromocriptine and lergotrile treatment of Parkinson's disease. Am J Psychiatry 135:1227–1229

    Google Scholar 

  • Shepard PD, German DC (1984) A subpopulation of mesocortical dopamine neurons possess autoreceptors. Eur J Pharmacol 114:401–402

    Google Scholar 

  • Skarsfeldt T (1992) Electrophysiological profile of the new atypical neuroleptic, sertindole, on midbrain dopamine neurons in rats: acute and repeated treatment. Synapse 10:25–33

    Google Scholar 

  • Spensley J, Rockwell DA (1972) Psychosis during methyl-phenidate abuse. N Engl J Med 286:880–881

    Google Scholar 

  • Stockton ME, Rasmussen K (1996) Electrophysiological effects of olanzapine, a novel atypical antipsychotic, on A9 and A10 dopamine neurons. Neuropsychopharmacology 14:97–104

    Google Scholar 

  • Wang RY (1981) Dopaminergic neurons in the rat vemtral tegmental area. III. Effects ofd- andl-amphetamiinie. Brain Res Rev 3:153–165

    Google Scholar 

  • Waszczak BL, Bergstrom DA, Walters JR (1981) Single unit responses of substantia nigra and globus pallidus neurons to GABA agonist and antagonist drugs. In: Di Chiara G, Gessa GL (eds) GABA and the basal ganglia. Raven Press, New York, pp 79–94

    Google Scholar 

  • White FJ, Wang RY (1983) Differential effects of classical and atypical antipsychotic drugs on A9 and A10 dopamine neurons. Science 221:1054–1057

    Google Scholar 

  • White FJ, Wang RX (1984) A10 dopamine neurons: role of autoreceptors in determining firing rate and sensitivity do dopamine agonists. Life Sci 34:1161–1170

    Google Scholar 

  • Young D, Scoville WB (1938) Paranoid psychosis in narcolepsy and the possible dangers of benzedrine treatment. Med Clin N Am 22:637–646

    Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, 46285, Indianapolis, IN, USA

    M. E. Stockton & K. Rasmussen

Authors
  1. M. E. Stockton
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. K. Rasmussen
    View author publications

    You can also search for this author in PubMed Google Scholar

Rights and permissions

Reprints and permissions

About this article

Cite this article

Stockton, M.E., Rasmussen, K. Olanzapine, a novel atypical antipsychotic, reversesd-amphetamine-induced inhibition of midbrain dopamine cells. Psychopharmacology 124, 50–56 (1996). https://doi.org/10.1007/BF02245605

Download citation

  • Received:

  • Revised:

  • Issue Date:

  • DOI: https://doi.org/10.1007/BF02245605

Key words

Search

Navigation